# A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

> **NCT05678270** · PHASE2 · RECRUITING · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma (ICC)

## Interventions

- **DRUG:** ICP-192

## Key facts

- **NCT ID:** NCT05678270
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-15
- **Primary completion:** 2026-05
- **Final completion:** 2026-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05678270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05678270, "A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05678270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*